EWM
AKBA icon

Edge Wealth Management’s Akebia Therapeutics AKBA Stock Holding History

Edge Wealth Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-500
Closed -$6K – 457
2014
Q4 		$6K Buy
+500
New +$7.17K ﹤0.01% 330

Other funds holding AKBA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Edge Wealth Management's AKBA Position: Q1 2015 in Review

Edge Wealth Management sold out of Akebia Therapeutics (AKBA) in Q1 2015, closing a stake of 500 shares — an estimated $6K sold.

Edge Wealth Management first reported a position in AKBA in Q4 2014 and held it in 1 quarter. The position peaked at $6K in Q4 2014. 61 funds tracked by Wall St. Rank hold AKBA as of Q1 2015.

  • Edge Wealth Management reported no remaining Akebia Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Edge Wealth Management sold 500 Akebia Therapeutics shares in Q1 2015, an estimated $6K.
  • Edge Wealth Management first reported a position in Akebia Therapeutics in Q4 2014 and held it in 1 quarter.
  • Edge Wealth Management's Akebia Therapeutics position peaked at $6K in Q4 2014.
  • 61 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2015.

Based on Edge Wealth Management's 13F filing for Q1 2015, filed 6 Apr 2015.